Northland Capital upgraded Endo Intl (NASDAQ:ENDP) from Market Perform to Outperform in a report released today.
- Updated: September 29, 2016
Northland Capital has upgraded Endo Intl (NASDAQ:ENDP) from Market Perform to Outperform in a statement released on 09/29/2016.
On 9/16/2016, Citigroup released a statement on Endo Intl (NASDAQ:ENDP) bumped down the target price from $40.00 to $25.00. At the time, this suggested an upside of 0.22%.
Boasting a price of $22.36, Endo Intl (NASDAQ:ENDP) traded -1.35% lower on the day. The last stock price is up 3.64% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same period. ENDP has recorded a 50-day average of $21.51 and a two hundred day average of $21.29. Trading volume was down over the average, with 1,606,023 shares of ENDP changing hands under the typical 6,900,490
With a total market value of $0, Endo Intl has 52 week low of $12.56 and a 52 week high of $72.85 .
In addition to Northland Capital reporting its target price, a total of 19 firms have reported on the stock. The consensus target price is $30.05 with 3 firms rating the stock a strong buy, 5 brokers rating the stock a buy, 13 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally zero equity analysts rating the company a sell.
Brief Synopsis About Endo Intl (NASDAQ:ENDP)
Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Branded Pharmaceuticals segment offers chronic pain management products, such as BELBUCA, OPANA ER, and Percocet; Lidoderm for opioid analgesics; and Voltaren gel for osteoarthritis pain, as well as XIAFLEX for treating PeyronieÂ’s and DupuytrenÂ’s contracture diseases. This segment also provides Supprelin LA for central precocious puberty treatment; testosterone replacement therapies, such as Aveed and TESTOPEL, as well as Fortesta and Testim gels; Frova and Sumavel DosePro for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; and Vantas for the palliative treatment of prostate cancer. The companyÂ’s U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, womenÂ’s health, and cardiovascular disease markets. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, womenÂ’s health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs. The company also provides Monarc subfascial hammock to treat female stress urinary incontinence; and Elevate transvaginal pelvic floor repair system for the treatment of pelvic organ prolapse. It sells its branded pharmaceuticals and generics directly, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.